JP2024508764A - 抗ｖｉｓｔａ抗体及びその使用 - Google Patents

抗ｖｉｓｔａ抗体及びその使用 Download PDF

Info

Publication number
JP2024508764A
JP2024508764A JP2023549992A JP2023549992A JP2024508764A JP 2024508764 A JP2024508764 A JP 2024508764A JP 2023549992 A JP2023549992 A JP 2023549992A JP 2023549992 A JP2023549992 A JP 2023549992A JP 2024508764 A JP2024508764 A JP 2024508764A
Authority
JP
Japan
Prior art keywords
seq
antibody
vista
antigen
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508764A5 (enExample
Inventor
ショーン ピー． イアドナト，
ティエリ ギロドー，
エリック ジェイ． タルチャ，
デイビッド スコット ジョンソン，
アダム シュルツ アドラー，
レナ アヴィヴァ ミズラヒ，
ヨン ウィアン リム，
マイケル アセンシオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Inc
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Inc filed Critical Kineta Inc
Publication of JP2024508764A publication Critical patent/JP2024508764A/ja
Publication of JP2024508764A5 publication Critical patent/JP2024508764A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023549992A 2021-02-18 2022-02-18 抗ｖｉｓｔａ抗体及びその使用 Pending JP2024508764A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150995P 2021-02-18 2021-02-18
US63/150,995 2021-02-18
PCT/US2022/016912 WO2022178203A1 (en) 2021-02-18 2022-02-18 Anti-vista antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024508764A true JP2024508764A (ja) 2024-02-28
JP2024508764A5 JP2024508764A5 (enExample) 2025-02-26

Family

ID=82931719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549992A Pending JP2024508764A (ja) 2021-02-18 2022-02-18 抗ｖｉｓｔａ抗体及びその使用

Country Status (11)

Country Link
US (1) US20240132593A1 (enExample)
EP (1) EP4294530A4 (enExample)
JP (1) JP2024508764A (enExample)
KR (1) KR20230157970A (enExample)
CN (1) CN117177995A (enExample)
AU (1) AU2022223973A1 (enExample)
BR (1) BR112023016533A2 (enExample)
CA (1) CA3208872A1 (enExample)
IL (1) IL305310A (enExample)
MX (1) MX2023009623A (enExample)
WO (1) WO2022178203A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014327A2 (en) * 2018-07-11 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
JP2020509756A (ja) * 2017-03-14 2020-04-02 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
WO2020140094A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h3 binding proteins and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020509756A (ja) * 2017-03-14 2020-04-02 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
WO2020014327A2 (en) * 2018-07-11 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IADONATO S. ET AL.: "76P Highly potent fully human anti-VISTA antibodies efficiently abrogate the interaction of this new", ANNALS OF ONCOLOGY, vol. vol.31, Supplement 7, JPN6025052557, 2020, pages 1448 - 1449, ISSN: 0005761631 *
JOHNSTON RJ. ET AL.: "VISTA is an acidic pH-selective ligand for PSGL-1", NATURE, vol. vol.574(7779), JPN6025052556, 2019, pages 565 - 570, ISSN: 0005761632 *

Also Published As

Publication number Publication date
EP4294530A4 (en) 2025-07-16
US20240132593A1 (en) 2024-04-25
KR20230157970A (ko) 2023-11-17
BR112023016533A2 (pt) 2023-11-21
CA3208872A1 (en) 2022-08-25
WO2022178203A1 (en) 2022-08-25
EP4294530A1 (en) 2023-12-27
CN117177995A (zh) 2023-12-05
MX2023009623A (es) 2023-10-23
AU2022223973A1 (en) 2023-09-07
IL305310A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
JP7456976B2 (ja) 抗ｃｔｌａ－４抗体およびその使用方法
KR102606252B1 (ko) 항-pd-1 항체로 암을 치료하는 방법
TWI791519B (zh) 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
JP6175590B1 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
JP2022509942A (ja) 抗ｎｋｇ２ａ抗体およびその使用
CN112513639B (zh) 用于成像的组合物和方法
RS64909B1 (sr) Anti-ctla-4 antitela i postupci za njihovu upotrebu
CN112638415B (zh) 用于成像的组合物和方法
CN114585644A (zh) 抗cd96抗体及其使用方法
JP2023536631A (ja) 多重特異性結合性作用剤およびその使用
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
KR20230156727A (ko) 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
US20260049136A1 (en) Anti-trem2 antibodies and methods of use
US20250109201A1 (en) Anti-ilt2 antibodies and uses thereof
JP2023536629A (ja) Ｃｄ４７結合性作用剤およびその使用
WO2021207681A1 (en) Targeted reduction of activated immune cells
JP2024508764A (ja) 抗ｖｉｓｔａ抗体及びその使用
JP2023536630A (ja) Ｐｄ－ｌ１結合性作用剤およびその使用
US20250361297A1 (en) Anti- siglec-15 binding molecules and methods of use
HK40076263A (en) Anti-cd96 antibodies and methods of use thereof
HK40048154B (zh) 用於成像的组合物和方法
HK40051925B (zh) 用於成像的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323